NO20080304L - Behandlingsmetoder ved bruk av hydrokinon-ansamyciner - Google Patents

Behandlingsmetoder ved bruk av hydrokinon-ansamyciner

Info

Publication number
NO20080304L
NO20080304L NO20080304A NO20080304A NO20080304L NO 20080304 L NO20080304 L NO 20080304L NO 20080304 A NO20080304 A NO 20080304A NO 20080304 A NO20080304 A NO 20080304A NO 20080304 L NO20080304 L NO 20080304L
Authority
NO
Norway
Prior art keywords
benzoquinone
hydroquinone
treatment
methods
ansamycins
Prior art date
Application number
NO20080304A
Other languages
English (en)
Norwegian (no)
Inventor
Yun Gao
Julian Adams
Asimina T Georges Evangelinos
Louis Grenier
Roger H Pak
James R Porter
Julia Brain
David Grayzel
Emmanuel Normant
Vito Palombella
Jeffrey K Tong
James L Wright
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of NO20080304L publication Critical patent/NO20080304L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20080304A 2005-07-13 2008-01-16 Behandlingsmetoder ved bruk av hydrokinon-ansamyciner NO20080304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/180,314 US20060019941A1 (en) 2003-12-23 2005-07-13 Analogs of benzoquinone-containing ansamycins and methods of use thereof
PCT/US2006/027113 WO2007009007A2 (en) 2005-07-13 2006-07-13 Methods of treatment using hydroquinone ansamycins

Publications (1)

Publication Number Publication Date
NO20080304L true NO20080304L (no) 2008-02-29

Family

ID=37637939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080304A NO20080304L (no) 2005-07-13 2008-01-16 Behandlingsmetoder ved bruk av hydrokinon-ansamyciner

Country Status (16)

Country Link
US (1) US20060019941A1 (es)
EP (1) EP1904057B1 (es)
JP (1) JP2009501234A (es)
KR (1) KR20080030093A (es)
CN (1) CN101267816A (es)
AT (1) ATE451919T1 (es)
AU (1) AU2006268196A1 (es)
BR (1) BRPI0612870A2 (es)
CA (1) CA2612506A1 (es)
DE (1) DE602006011161D1 (es)
ES (1) ES2337397T3 (es)
IL (1) IL188355A0 (es)
MX (1) MX2007016469A (es)
NO (1) NO20080304L (es)
WO (1) WO2007009007A2 (es)
ZA (1) ZA200800906B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492261B1 (en) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2006098761A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
EP1906950A4 (en) * 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
WO2010021752A1 (en) * 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US8778921B2 (en) * 2008-10-15 2014-07-15 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
JP6637442B2 (ja) 2014-05-01 2020-01-29 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 補体b因子発現を調節するための組成物及び方法
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115227692A (zh) * 2022-09-05 2022-10-25 中国医学科学院基础医学研究所 Reblastatin在制备治疗慢性惊厥的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) * 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
AU3225693A (en) * 1992-01-06 1993-08-03 Pfizer Inc. Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
CA2166320A1 (en) * 1993-06-29 1995-01-12 Randall James Gallaschun Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
DE60213386T2 (de) * 2001-03-30 2006-11-23 The United States Of America Represented By The Secretary, Department Of Health And Human Services Geldanamycinderivate zur krebsbehandlung
EP1420747A4 (en) * 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2474508A1 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
EP2492261B1 (en) * 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
WO2006098761A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor

Also Published As

Publication number Publication date
KR20080030093A (ko) 2008-04-03
ZA200800906B (en) 2009-07-29
WO2007009007A3 (en) 2007-05-03
CA2612506A1 (en) 2007-01-18
US20060019941A1 (en) 2006-01-26
BRPI0612870A2 (pt) 2010-11-30
JP2009501234A (ja) 2009-01-15
EP1904057A2 (en) 2008-04-02
IL188355A0 (en) 2008-08-07
CN101267816A (zh) 2008-09-17
MX2007016469A (es) 2008-04-22
AU2006268196A1 (en) 2007-01-18
ATE451919T1 (de) 2010-01-15
ES2337397T3 (es) 2010-04-23
WO2007009007A2 (en) 2007-01-18
EP1904057B1 (en) 2009-12-16
DE602006011161D1 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
NO20080304L (no) Behandlingsmetoder ved bruk av hydrokinon-ansamyciner
NO20062707L (no) Analoger av benzokinon-inneholdende ansamyciner for behandling av kreft
CY1119485T1 (el) Αναστολεις ινδαζολης του σηματοδοτικου μονοπατιου wnt και θεραπευτικες χρησεις αυτων
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2008024304A3 (en) Compounds for treatment of proliferative disorders
UA100983C2 (ru) Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201000098A1 (ru) Производные хиназолинамида
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
EA200700909A1 (ru) Азаиндолкарбоксамиды
BRPI0507968A (pt) oxidação de compostos orgánicos a ph alto
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201001286A1 (ru) Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза
BRPI0911907B8 (pt) processo para produzir uma composição contendo triptofano e composição proteica contendo triptofano
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
TW200728258A (en) Novel compounds
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA201190004A1 (ru) Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application